Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which contrast agent gives clearer heart artery images?

NCT ID NCT05065073

Disease control Sponsor: Minneapolis Heart Institute Foundation Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 19, 2026 · Last updated Aug 20, 2026 · Updated 1 time

Summary

This trial compares two types of contrast agents used during optical coherence tomography (OCT), a test that takes detailed pictures of the heart's arteries. The study will see if one agent uses less contrast, produces clearer images, and causes fewer heart rhythm changes than the other. Adults with coronary artery disease who are already scheduled for OCT will be randomly assigned to receive either the iso-osmolar or low-osmolar contrast agent.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Iodixanol (iso-osmolar contrast) and Iohexol (low-osmolar contrast)
What this could lead to
If one contrast agent works better, it could make OCT imaging safer and more efficient for people with coronary artery disease.
What could go wrong
This is a small, single-center trial, so results may not apply broadly. The study focuses on imaging details, not long-term patient outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

62 people

The number who actually took part.

Started

Sep 2021

Finished

Jun 2023

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 years or greater 2. Willing and able to give informed consent. The patients must be able to comply with study procedures 3. Undergoing clinically-indicated coronary angiography and OCT Exclusion Criteria 1. Baseline electrocardiographic changes hindering interpretation (such as left bundle-branch block, and \>1 mm ST segment depression) 2. Emergency cardiac catheterization (for example in patients with ST-segment elevation acute myocardial infarction) 3. Inability to provide symptomatic assessment 4. Known allergy to contrast

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Contrast media reaction are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contrast media reaction Coronary artery disease

Contacts and locations

Locations

  • Minneapolis Heart Institute Foundation

    Minneapolis, Minnesota, 55407, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.